VNDA
Vanda Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.43
+1.69%Aug 24, 2026, 11:00 UTC
Vanda Pharmaceuticals announced that the European Commission granted Orphan Designation to its investigational drug imsidolimab for the treatment of Generalized Pustular Psoriasis, based on a positive opinion from the EMA's Committee for Orphan Medicinal Products.
Source:Aug 5, 2026, 20:01 UTC
Vanda Pharmaceuticals announced that NEREUS for prevention of vomiting induced by motion became commercially available in Q2 2026.
Source:Aug 5, 2026, 20:01 UTC
Vanda Pharmaceuticals reported second quarter 2026 financial results, with Fanapt net product sales up 23% to $36.0 million and total prescriptions up 31%.
Jul 15, 2026, 20:30 UTC
Vanda Pharmaceuticals announced that its NEREUS (tradipitant) will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.
Source:Jul 7, 2026, 20:30 UTC
The FDA granted Rare Pediatric Disease Designation to Vanda Pharmaceuticals' investigational therapy VCA-894A for Charcot-Marie-Tooth disease type 2S.
Source: